Refreshing results…
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
UploadDistinct representation of muscle weakness in QMG and MG-ADL
UploadLongitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity
UploadMissing publications? Search for publications with a matching author name.